| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8735393 | ALMIRALL | Anhydrous topical skin preparations |
Dec, 2018
(5 years ago) | |
| US7179475 | ALMIRALL | Anhydrous topical skin preparations |
Dec, 2018
(5 years ago) | |
| US8232276 | ALMIRALL | Anhydrous topical skin preparations |
Nov, 2020
(3 years ago) | |
Xolegel is owned by Almirall.
Xolegel contains Ketoconazole.
Xolegel has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Xolegel are:
- US8735393
- US7179475
- US8232276
Xolegel was authorised for market use on 28 July, 2006.
Xolegel is available in gel;topical dosage forms.
Xolegel can be used as treatment of seborrhea dermatitis in humans.
The generics of Xolegel are possible to be released after 24 November, 2020.
Drugs and Companies using KETOCONAZOLE ingredient
Market Authorisation Date: 28 July, 2006
Treatment: Treatment of seborrhea dermatitis in humans
Dosage: GEL;TOPICAL
More Information on Dosage
XOLEGEL family patents
